WT-EGFR was reported to confer acquired resistance to third generation of EGFR TKIs and maintain the mutated KRAS activity as well as KRAS-driven tumorigenesis (another critical driving factor of NSCLC)9,11,46. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.